Douglas M. Hunt, Senior Vice President of Regulatory Affairs at Puma Biotechnology, Inc. (NASDAQ:PBYI), disposed of 8,460 shares of the company’s common stock on July 6, 2026. The shares were sold at a price of $8.263 per share, totaling $69,904.
The transaction was conducted as part of a pre-arranged 10b5-1(c) sell to cover program, which was adopted on December 14, 2020. Following this sale, Mr. Hunt directly holds 196,841 shares of Puma Biotechnology common stock. The sale occurred as the stock trades near its 52-week high of $8.44, following a remarkable 126% gain over the past year. According to InvestingPro analysis, PBYI appears undervalued with a Fair Value of $13, suggesting potential upside for remaining shareholders. The company is among the most undervalued stocks tracked by InvestingPro, which offers a comprehensive Pro Research Report covering this and 1,400+ other US equities.
In other recent news, Puma Biotechnology reported its first-quarter 2026 earnings, revealing a net loss per share that fell short of analyst expectations. The company posted an earnings per share (EPS) of -$0.04, missing the forecasted break-even point of $0.00. Revenue for the quarter was $44.8 million, which was below the anticipated $49 million, marking a revenue shortfall of 8.57%. Additionally, Puma Biotechnology held its 2026 Annual Meeting of Stockholders, where shareholders elected eight directors to serve one-year terms until the next annual meeting in 2027. The directors elected include Alan H. Auerbach, Alessandra Cesano, and Allison Dorval, among others. Voting results for each nominee ranged significantly, with shares in favor ranging from 32,546,955 to 37,472,173. There were also 6,064,713 broker non-votes for each nominee. These developments come amid investor reactions to the company’s recent financial performance.